×

Global Single Use Bioreactor (Recombinant Proteins, Monoclonal Antibodies) Market - Forecast to 2019

Dublin, Dec. 1, 2014 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/wnw98g/single_use) has announced the addition of the "Single Use Bioreactor Market by Product Type, Cell Type, Technology, End User - Global Forecast to 2019" report to their offering.

The single use bioreactors (SUBs) market is expected to grow at a double digit CAGR of 18.4% to reach $470.9 million by 2019 from $202.5 million in 2014. Major factors fueling the growth of this market are low requirements of capital investment for setting up the facility, reduced complexity of automation, and energy efficiency. However, regulatory concerns regarding the mixing process, contamination by leachables and extractable, and difficulties in meeting good manufacturing practices (GMP) standards are restricting the growth of the single use bioreactor market.

The single use bioreactor market is segmented on the basis of molecule type (monoclonal antibodies (MAbs), vaccines, gene therapy, recombinant proteins, stem cells, and others (growth factors, interferons, antisense, RNA interference)), type of cell (mammalian cell, bacterial cell, yeast cell and others (insect cell and plant cell)), technology (wave-induced motion SUBs, stirred SUBs, single-use bubble column bioreactors, and others (single-use reactors with vertically perforated discs and single-use hybrid reactors)), end users (R&D (CROs, biopharmaceutical manufacturers, and research institutes) and biopharmaceutical manufacturers), and region (North America, Europe, Asia-Pacific, RoW).

MAbs is the largest segment of the single use bioreactor market by molecule type. The high growth rate of this segment can be attributed to the growing demand for SUBs in small-scale manufacturing of MAbs as a result of low investment costs, low requirement of manpower, reduction in time-consuming changeover procedures.

The mammalian cells segment of the market by type of cell is the largest and fastest-growing segment, owing to successful employment of SUB for mammalian cell cultures for clinical and commercial drug manufacturing.

The R&D department of CROs, biopharmaceutical manufacturers, and research institutes is the major end-user segment of the single use bioreactor market.

The SUB market is dominated by Europe, followed by North America. However, the Asia-Pacific region is expected to grow at the highest CAGR during the forecast period.

Key players operating in the single use bioreactor market are Thermo Fischer Scientific, Inc. (U.S.), Sartorius AG (Germany), Merck KGaA (Germany), GE Healthcare (U.S.), and Pall Corporation (U.S.)


Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Industry Insights

7 Single Use Bioreactor Market, By Technology

8 Single Use Bioreactor Market, By Molecule Type

9 Single Use Bioreactor Market, By Type Of Cell

10 Single Use Bioreactor Market, By End User

11 Single Use Bioreactor Market, By Geography

12 Competitive Landscape

13 Company Profiles

14 Appendix


Companies Mentioned:

  • Applikon Biotechnology
  • Cellexus Limited
  • Cellution Biotech
  • GE Healthcare (Subsidiary Of General Electric Company)
  • Merck Kgaa
  • Pall Corporation
  • Parker Hannifin Corporation
  • Pbs Biotech, Inc.
  • Sartorius Ag
  • Thermo Fisher Scientific, Inc.


For more information visit http://www.researchandmarkets.com/research/wnw98g/single_use

CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Sector: Biotechnology

Source:Research and Markets